2024-03-13 15:19:00
Despite the increased risk of developing cardiovascular disease
A cohort study of a Swedish population found that initiation of drug therapy in people with attention deficit hyperactivity disorder (ADHD) was associated with significantly lower rates of all-cause mortality, especially mortality from unnatural causes. How reported V The Journal of the American Medical AssociationThe results of this study are important because it has previously been reported that there is an increased risk of cardiovascular disease with ADHD medications.
According to the World ADHD Federation 2021, the syndrome amazes 5.9 percent of youth and 2.5 percent of adults worldwide. He connected with a wide range of comorbid mental and physical illnesses, as well as adverse functional outcomes. Additionally, people with ADHD are at risk of premature death rises approximately twice.
Randomized controlled trials have demonstrated that ADHD medications are effective in reducing the core symptoms of ADHD. Pharmacoepidemiological studies have also shown a reduction in the risk of injuries, road traffic accidents and crime, which is expected will lead to reduce the mortality rate. However, there are concerns about the risk of cardiovascular disease that increases with long-term use of ADHD medications.
A research team led by Zheng Chang from the Karolinska Institute used Swedish national registries to examine whether initiation of ADHD medication is associated with mortality in children, youth and adults. The analysis included data from 148,578 patients diagnosed with ADHD (61,356 women, 87,222 men). The mean age at baseline was 17.4 years. A total of 632 people died during the two-year follow-up period, and 1,402 died during the five-year period. Two thirds of deaths were due to unnatural causes.
Within three months of being diagnosed with ADHD, 84,204 people started medication treatment for ADHD, while 64,296 did not. The two-year overall mortality rate was lower among those who started treatment for ADHD (17.3 per 10,000 people) compared to those who did not start treatment (31.8 per 10,000 people). During the 2-year follow-up period, initiation of ADHD treatment was significantly associated with lower rates of all-cause mortality (relative risk 0.79) and non-natural cause mortality (relative risk 0.75). When analyzing specific unnatural causes of death, a significantly lower risk of death due to accidental poisoning was observed after initiation of ADHD treatment (relative risk 0.47).
In a subgroup analysis, the researchers found that starting ADHD medication was significantly associated with lower rates of all-cause and non-natural-cause mortality among children and youth 6 to 24 years of age and adults 25 to 64 years of age. The risk reduction was also greater in men. When the follow-up period was extended to five years, the associations weakened for most outcomes but remained statistically significant for mortality from unnatural causes.
These results suggest that the benefits of taking ADHD medications outweigh the associated risks. However, to fully understand the safety profile of these drugs, it is necessary to study mortality rates from natural causes, and in particular from cardiovascular diseases.
We previously reported that maternal use of dexamphetamine and methylphenidate, drugs for ADHD, during pregnancy does not increase the risk of neurodevelopmental disorders in children.
1710386313
#ADHD #medications #reduced #deaths #among #people #condition